Head-To-Head Contrast: Tevogen Bio (NASDAQ:TVGN) & Qiagen (NYSE:QGEN)

Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk and Volatility

Tevogen Bio has a beta of -1.14, suggesting that its share price is 214% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

Profitability

This table compares Tevogen Bio and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	-396.07%	749.97%
Qiagen	4.23%	13.92%	8.40%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Tevogen Bio and Qiagen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	0	0	1	0	3.00
Qiagen	0	7	3	0	2.30

Tevogen Bio currently has a consensus price target of $4.20, suggesting a potential upside of 228.13%. Qiagen has a consensus price target of $47.71, suggesting a potential upside of 24.50%. Given Tevogen Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Qiagen.

Earnings and Valuation

This table compares Tevogen Bio and Qiagen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A
Qiagen	$1.98 billion	4.30	$83.59 million	$0.36	106.44

Qiagen has higher revenue and earnings than Tevogen Bio.

Insider and Institutional Ownership

70.0% of Qiagen shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Qiagen beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.